Latest Aveo Pharmaceuticals (AVEO) Headlines
AVEO Announces Timing for Conference Call to Discuss Year-End 2013 Financial Results and Provide Strategic Update for 2014
Business Wire - Tue Mar 04, 5:30AM CST
AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company's fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014. AVEO will host a conference call to discuss the company's financial results as well as provide an update on strategy for 2014 on Thursday, March 13 at 4:30 p.m. (ET). The call can be accessed by dialing 1-866-318-8613 (domestic) or 1-617-399-5132 (international) five minutes prior to the start of the call and providing the passcode 57921892. A replay of the call will be available two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 61612931. The replay will be available for two weeks from the date of the live call.
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.
AVEO/Astellas Terminate Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 3:30PM CST
AVEO Pharma and Astellas announced their decision to terminate their agreement for the development and commercialization of tivozanib.
AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib
Business Wire - Fri Feb 14, 4:30AM CST
--AVEO to Outline Corporate Strategy During 2013 Financial Results Conference Call on March 13, 2014
Catabasis Announces Appointment of Kenneth M. Bate as Independent Director
PR Newswire - Tue Feb 04, 7:00AM CST
Catabasis Pharmaceuticals Inc. today announced the appointment of Kenneth M. Bate to its board of directors as an independent director. Mr. Bate is an experienced biotechnology executive having led companies at various stages of development. He currently is chairman of the board of Cubist Pharmaceuticals, Inc., and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and TransMedics, Inc. Mr. Bate currently serves as an independent biotechnology industry consultant and previously has served as president and chief executive officer of Archemix Corp. and NitroMed Inc., chief financial officer of Millennium Pharmaceuticals Inc. and Biogen Inc., and co-founded JSB Partners LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. He holds an MBA from the Wharton School of the University of Pennsylvania and a BA from Williams College.
Newport, Target, AVEO Pharmaceuticals, Astellas Pharma and Bristol-Myers Squibb highlighted as Zacks Bull and Bear of the Day
PR Newswire - Mon Feb 03, 8:30AM CST
Zacks Equity Research highlights Newport Corporation (Nasdaq:NEWP-Free Report) as the Bull of the Day and Target (NYSE:TGT-Free Report)as the Bear of the Day. In addition, Zacks Equity Research provides analysis onAVEO Pharmaceuticals, Inc. (Nasdaq:AVEO-Free Report), Astellas Pharma, Inc. (OTC:ALPMY-Free Report) and Bristol-Myers Squibb (NYSE:BMY-Free Report).
AVEO/Astellas Terminate Tivozanib Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 4:10PM CST
AVEO Pharmaceuticals and partner Astellas Pharma announced their decision to discontinue a phase II study evaluating tivozanib in patients suffering from locally recurrent or metastatic triple negative breast cancer.
AVEO and Astellas Discontinue Phase 2 Trial of Tivozanib in Breast Cancer
Business Wire - Thu Jan 30, 5:30AM CST
AVEO Oncology (NASDAQ: AVEO) today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment. AVEO previously announced that enrollment in this study had been slower than anticipated, and enrollment rates did not improve substantially following additional patient recruitment efforts.
Biotech 2013 by the Numbers: A Blockbuster Year
at The Street - Wed Jan 01, 8:13AM CST
The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.
AVEO Pharmaceuticals, Inc. (AVEO) Catches Eye: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 7:44AM CST
AVEO Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise by 8% on the day.
ImmunoGen names Aveo's Johnston as new CFO
AP - Mon Dec 30, 10:37AM CST
WALTHAM, Mass. (AP) — Drug developer ImmunoGen on Monday named David Johnston, who had been chief financial officer of Aveo Pharmaceuticals Inc., as its new CFO.
The Worst Biotech CEO of 2013 Is...
at The Street - Tue Dec 17, 6:58AM CST
Vical's Vijay Samant is this year's CEO loser by a wide margin.
AVEO Falls on Tivozanib News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 4:20PM CST
AVEO Pharmaceuticals announced that data from a planned interim analysis of the phase II BATON study on tivozanib showed that the study is unlikely to meet the primary endpoint.
AVEO Provides Update on Interim Analysis from Tivozanib Trial in Colorectal Cancer
Business Wire - Fri Dec 13, 5:50AM CST
AVEO Oncology (NASDAQ: AVEO) today announced that data from a planned interim analysis of the Phase 2 BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population.
Your Vote Counts: Who is the Worst Biotech CEO of 2013?
at The Street - Thu Dec 12, 7:32AM CST
Amarin, Ariad, Vical, Dendreon and Aveo. You get to decide which CEO deserves to wear the badge of shame.
AVEO Q3 Loss Wider than Expected, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 12, 7:30AM CST
AVEO Pharmaceuticals reported third quarter 2013 loss of 47 cents per share.
AVEO Reports Third Quarter 2013 Financial Results
Business Wire - Thu Nov 07, 5:32AM CST
AVEO Oncology (NASDAQ: AVEO) today reported its third quarter 2013 financial results.
5 Biotech Stocks Under $10 for Your Watch List
at The Street - Fri Oct 25, 6:00AM CDT
Flagship VentureLabs Launches Midori Renewables
PR Newswire - Wed Sep 04, 12:18PM CDT
Flagship VentureLabs announced today that Midori Renewables is globally deploying their Breaking the Biomass Barrier(TM) technology, a novel catalyst that melts non-food biomass into low cost sugar, enabling the production of many valuable renewable products and animal feed. Midori's catalyst is a solid material, not an enzyme, micro-organism, or aqueous acid, that can be easily separated from the reaction and reused, resulting in a significantly lower cost solution than existing technologies.
AVEO Oncology to Present at the Morgan Stanley Global Healthcare Conference
Business Wire - Wed Sep 04, 5:30AM CDT
AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2013 at 12:55 p.m. (ET) in New York City.